{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.4","upperLimit":"54.9","value":"36.4"},{"groupId":"OG001","lowerLimit":"2.5","upperLimit":"31.2","value":"12.0"}]}],"title":"By Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"28.1","upperLimit":"63.6","value":"45.5"},{"groupId":"OG001","lowerLimit":"31.3","upperLimit":"72.2","value":"52.0"}]}],"title":"By Cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"33.5","upperLimit":"69.2","value":"51.5"},{"groupId":"OG001","lowerLimit":"34.9","upperLimit":"75.6","value":"56.0"}]}],"title":"By Cycle 9"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.2","upperLimit":"74.5","value":"57.6"},{"groupId":"OG001","lowerLimit":"42.5","upperLimit":"82.0","value":"64.0"}]}],"title":"By Cycle 12"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.2","upperLimit":"74.5","value":"57.6"},{"groupId":"OG001","lowerLimit":"46.5","upperLimit":"85.1","value":"68.0"}]}],"title":"By Cycle 18"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.2","upperLimit":"74.5","value":"57.6"},{"groupId":"OG001","lowerLimit":"46.5","upperLimit":"85.1","value":"68.0"}]}],"title":"By Cycle 24"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"39.2","upperLimit":"74.5","value":"57.6"},{"groupId":"OG001","lowerLimit":"54.9","upperLimit":"90.6","value":"76.0"}]}],"title":"By Cycle 36"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.1","upperLimit":"77.1","value":"60.6"},{"groupId":"OG001","lowerLimit":"54.9","upperLimit":"90.6","value":"76.0"}]}],"title":"By Cycle 48"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.1","upperLimit":"77.1","value":"60.6"},{"groupId":"OG001","lowerLimit":"54.9","upperLimit":"90.6","value":"76.0"}]}],"title":"By Cycle 66"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"description":"BCR-ABL is the fusion gene from breakpoint cluster region and Abelson genes. BCR-ABL transcript levels were summarized by cohort and time point. MMR is defined as ≤ 0.1% BCR-ABL/control gene (ABL) % by international scale, or equivalent to ≥ 3 log reduction of BCR-ABL transcript from standardized baseline, measured by RQ-PCR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients resistant or intolerant to either imatinib or dasatinib","id":"OG000","title":"Resistant/Intolerant Ph+ CML in CP"},{"description":"Patients newly diagnosed in Chronic phase. Diagnosis within 6 months of date of first cytogenetic analysis confirming Philadelphia chromosome with (9;22) translocation by standard conventional cytogenetic analysis.","id":"OG001","title":"Newly Diagnosed and Untreated Ph+ CML in First CP"}],"paramType":"NUMBER","populationDescription":"Full Analysis Set (FAS): All patients who received at least one dose of study medication.","reportingStatus":"POSTED","timeFrame":"By 3, 6, 9, 12, 18, 24, 36, 48, 66 cycles","title":"Pharmacodynamics (BCR-ABL Transcript Levels Determined With Standard Protocols in Peripheral Blood): Best MMR Status by Cycle","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}